Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

ARS Pharmaceuticals (SPRY) EBIT Margin: 2022-2025

Historic EBIT Margin for ARS Pharmaceuticals (SPRY) over the last 3 years, with Sep 2025 value amounting to -163.66%.

  • ARS Pharmaceuticals' EBIT Margin rose 88798.00% to -163.66% in Q3 2025 from the same period last year, while for Sep 2025 it was -63.59%, marking a year-over-year increase of 226536.00%. This contributed to the annual value of -3.46% for FY2024, which is 22506321.00% up from last year.
  • ARS Pharmaceuticals' EBIT Margin amounted to -163.66% in Q3 2025, which was up 45.98% from -302.95% recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' EBIT Margin peaked at 54.51% during Q4 2024, and registered a low of -206,030.00% during Q2 2023.
  • In the last 3 years, ARS Pharmaceuticals' EBIT Margin had a median value of -758.97% in 2025 and averaged -38,074.13%.
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by 20,466,276bps in 2023, then soared by 20,296,200bps in 2024.
  • ARS Pharmaceuticals' EBIT Margin (Quarterly) stood at -3,507.94% in 2022, then tumbled by 20,466,276bps to -206,030.00% in 2023, then skyrocketed by 20,296,200bps to 54.51% in 2024, then soared by 88,798bps to -163.66% in 2025.
  • Its EBIT Margin stands at -163.66% for Q3 2025, versus -302.95% for Q2 2025 and -466.29% for Q1 2025.